Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
Seeking Alpha8/14/2026Neutral
KYNB
Kyntra Bio, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$27.57M
P/E Ratio
—
EPS
$-7.50
Beta
1.04
52W High
$12.60
52W Low
$6.32
50-Day MA
$7.07
200-Day MA
$7.78
Dividend Yield
—
Profit Margin
3969.00%
Forward P/E
61.35
PEG Ratio
—
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is headquartered in San Francisco, California.
Fundamentals
| Revenue (TTM) | $4.62M |
| Gross Profit (TTM) | $-23.23M |
| EBITDA | $-50.03M |
| Operating Margin | 1192.00% |
| Return on Equity | 0.00% |
| Return on Assets | -22.50% |
| Revenue/Share (TTM) | $1.14 |
| Book Value | $-10.82 |
| Price-to-Book | 80.40 |
| Price-to-Sales (TTM) | 5.97 |
| EV/Revenue | 17.1 |
| EV/EBITDA | 44.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 36.50% |
| Shares Outstanding | $4.05M |
| Float | $3.56M |
| % Insiders | 2.02% |
| % Institutions | 24.68% |
Historical Volatility
HV 10-Day
39.48%
HV 20-Day
33.46%
HV 30-Day
36.32%
HV 60-Day
35.19%
HV Rank
11.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($39.00 target)
2
Buy1
HoldLatest News
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the second quarter 2026 and provided an update on the company's recent developments.
GlobeNewsWire8/13/2026Neutral
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research8/3/2026Positive
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) treated with roxadustat will be presented as a poster at the European Hematology Association (EHA) Congress 2026, taking place June 11-14, 2026 in Stockholm, Sweden.
GlobeNewsWire6/11/2026Neutral
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
Seeking Alpha5/12/2026Neutral
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the first quarter 2026 and provided an update on the company's recent developments.
GlobeNewsWire5/11/2026Neutral
Kyntra Bio to Report First Quarter 2026 Financial Results
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
GlobeNewsWire5/4/2026Neutral
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know
Kyntra Bio (KYNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research4/14/2026Positive
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026.
GlobeNewsWire4/8/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KYNB and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026